The U.S. Supreme Court said it will hear an appeal by Rochester, Minn.-based Mayo Clinic, which is challenging two patents for tests that determine drug dosages to treat autoimmune diseases, according to a Wall Street Journal report.
Mayo says the patents, which belong to San Diego-based Prometheus Laboratories, aren’t valid because the pharmaceutical company is claiming a monopoly right to observe how the human body reacts to certain drugs — a biological phenomenon. Several medical associations have backed Mayo’s appeal, noting patents like Prometheus’ could hinder the practice of medicine and increase the costs of medical treatment.
Prometheus denies laying claim to a natural phenomenon. Supporters say the patent incentives are necessary to attract the private investment that leads to advances in therapeutic medicine.
The Supreme Court will hear the Mayo appeal during its next term, which begins in October.
Read the Wall Street Journal report on Mayo Clinic’s appeal in the Supreme Court.
Related Articles on Mayo Clinic:
Mayo Clinic in Minnesota Receives $750K for Expansion Project
No Medicare ACOs For Mayo Clinic
Donation Allows Telemedicine to Continue Between Phoenix Hospital, Mayo Clinic
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
